Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 57.67M | 84.51M | 75.74M | 68.79M | 45.60M |
Gross Profit | 36.80M | 61.62M | 44.97M | 36.71M | 31.00M |
EBITDA | -104.49M | -135.72M | -190.47M | -146.17M | -87.82M |
Net Income | -46.00M | -60.64M | -86.58M | -64.70M | -46.53M |
Balance Sheet | |||||
Total Assets | 144.22M | 167.53M | 294.30M | 396.50M | 328.83M |
Cash, Cash Equivalents and Short-Term Investments | 57.26M | 80.93M | 178.27M | 305.74M | 233.35M |
Total Debt | 75.96M | 88.59M | 127.34M | 74.98M | 89.08M |
Total Liabilities | 145.87M | 165.94M | 244.28M | 170.63M | 131.84M |
Stockholders Equity | 22.74M | 22.54M | 41.72M | 108.67M | 100.34M |
Cash Flow | |||||
Free Cash Flow | -95.19M | -136.32M | -182.46M | -132.89M | -90.85M |
Operating Cash Flow | -80.19M | -128.22M | -179.40M | -116.54M | -83.68M |
Investing Cash Flow | -15.00M | -2.10M | -22.93M | 40.51M | -7.16M |
Financing Cash Flow | 70.64M | 32.74M | 75.32M | 148.99M | 172.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
51 Neutral | $48.67M | ― | -546.55% | ― | 127.51% | 56.94% | |
50 Neutral | $54.78M | 2.40 | -50.81% | ― | -11.11% | 79.74% | |
48 Neutral | $57.07M | ― | -181.84% | ― | -32.11% | 88.12% | |
44 Neutral | $50.61M | ― | -1131.02% | ― | ― | 23.55% | |
38 Underperform | $22.18M | ― | -1949.77% | ― | -89.76% | 80.28% | |
27 Underperform | $147.54M | ― | -102.48% | ― | ― | -7.78% |
On July 16, 2025, AstraZeneca announced that its Phase III clinical trial for anselamimab, a treatment for AL amyloidosis originally developed by Caelum Biosciences, did not achieve statistical significance for its primary endpoint in certain patient stages. Despite this, the drug showed clinically meaningful improvements in a specific subgroup and was well tolerated, prompting AstraZeneca to continue evaluating the results and plan further discussions with global health authorities.
The most recent analyst rating on (FBIO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.
On May 30, 2025, Fortress Biotech‘s subsidiary, Checkpoint Therapeutics, merged with Sun Pharmaceutical Industries, resulting in Checkpoint becoming a wholly-owned subsidiary of Sun Pharma and deconsolidated from Fortress. This transaction provides Fortress with $28 million in cash and potential additional earnings through a regulatory milestone and royalty payments, impacting its financial structure and future revenue streams.
The most recent analyst rating on (FBIO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.